$12m just the start for Heptares deal with Japanese company
Heptares Therapeutics in Welwyn has entered into a drug discovery and licensing agreement with Daiichi Sankyo Company, the second largest pharmaceutical company in Japan.
The deal is focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain.
Daiichi Sankyo will receive exclusive global rights to develop, manufacture and commercialise novel, small molecules discovered by Heptares focused on the nominated GPCR.
Heptares will receive an upfront payment of $4 million, research funding of approximately $8m and is eligible to receive additional research, development and commercialisation milestone payments.
Heptares will also be eligible to receive royalties on net sales of products resulting from the alliance.
Malcolm Weir, Heptares CEO and chief R & D officer of parent company Sosei said: “This is a very exciting new collaboration as relieving pain presents a significant challenge.
“We are confident that the unique structural insights of the receptor that our technologies can deliver combined with expertise on its role in pain from the neurosciences team at Daiichi Sankyo will yield new, differentiated molecules that can be advanced into development.”
• PHOTOGRAPH SHOWS: Malcolm Weir